Literature DB >> 28251611

Consensus statement for the treatment of infantile haemangiomas with propranolol.

Sarah L Smithson1, Marius Rademaker2, Susan Adams3, Stuart Bade4, Philip Bekhor1, Samantha Davidson4, Amanda Dore4, Catherine Drummond5, Gayle Fischer6, Alexander Gin1, Claire Grills1, Anne Halbert7, Zerina Lokmic8, Emma McCahon9, Vanessa A Morgan1, Dedee F Murrell10, David Orchard1, Anthony Penington1, Diana Purvis11, John Relic12, Susan Robertson1, Aaron J Robinson1, Laura Scardamaglia1, John Su1, Swee Tan13, Orli Wargon14, Lachlan Warren15, Li-Chuen Wong9, Tania Zappala4, Roderic Phillips1.   

Abstract

Although most infantile haemangiomas do not require treatment due to a natural history of spontaneous involution, some require early intervention. The Australasian Vascular Anomalies Network and the Australasian Paediatric Dermatology Network have developed a consensus statement for the treatment of infantile haemangiomas with oral propranolol. Infants with haemangiomas that are life threatening, at risk of ulceration, or at risk of causing a significant functional impairment, psychological impact or physical deformity should be treated early with oral propranolol. Oral propranolol is safe and effective and in most healthy infants oral propranolol can be started in an outpatient setting.
© 2017 The Australasian College of Dermatologists.

Entities:  

Keywords:  Australian; New Zealand; beta-blocker; consensus; hemangioma; infantile haemangioma; propranolol; vascular anomaly

Mesh:

Substances:

Year:  2017        PMID: 28251611     DOI: 10.1111/ajd.12600

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  5 in total

Review 1.  Insights Into Vascular Anomalies, Cancer, and Fibroproliferative Conditions: The Role of Stem Cells and the Renin-Angiotensin System.

Authors:  Ethan J Kilmister; Swee T Tan
Journal:  Front Surg       Date:  2022-04-27

2.  Plasma Drug Concentration of Propranolol and Genetic Study in Chinese Han Patients With Infantile Haemangioma.

Authors:  Li Li; Lu Yu; Huan He; Li Wei; Zigang Xu; Libo Zhao; Yujuan Sun; Bin Zhang; Yuanxiang Liu; Rui He; Xiaoling Wang; Lin Ma
Journal:  Front Pediatr       Date:  2022-05-02       Impact factor: 3.569

3.  LncRNA OIP5-AS1 Promotes the Proliferation of Hemangioma Vascular Endothelial Cells via Regulating miR-195-5p/NOB1 Axis.

Authors:  Jiayu Zhang; Tiancheng Zhao; Leilei Tian; Yezhou Li
Journal:  Front Pharmacol       Date:  2019-04-24       Impact factor: 5.810

4.  Utility of the Infantile Hemangioma Referral Score (IHReS) as a decision-making tool for referral to treatment.

Authors:  Kanokporn Chitpiromsak; Leelawadee Techasatian; Charoon Jetsrisuparb
Journal:  BMJ Paediatr Open       Date:  2021-09-15

5.  Management of infantile hemangiomas during the COVID pandemic.

Authors:  Ilona J Frieden; Katherine B Püttgen; Beth A Drolet; Maria C Garzon; Sarah L Chamlin; Elena Pope; Anthony J Mancini; Christine T Lauren; Erin F Mathes; Dawn H Siegel; Deepti Gupta; Anita N Haggstrom; Megha M Tollefson; Eulalia Baselga; Kimberly D Morel; Sonal D Shah; Kristen E Holland; Denise M Adams; Kimberly A Horii; Brandon D Newell; Julie Powell; Catherine C McCuaig; Amy J Nopper; Denise W Metry; Sheilagh Maguiness
Journal:  Pediatr Dermatol       Date:  2020-05-16       Impact factor: 1.997

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.